S
NAMS icon

SignatureFD’s NewAmsterdam Pharma NAMS Stock Holding History

SignatureFD’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-647
Closed -$22.7K – 3554
2025
Q4 		$22.7K Hold
647
– – ﹤0.01% 2061
2025
Q3 		$18.4K Hold
647
– – ﹤0.01% 2146
2025
Q2 		$11.7K Sell
647
-42
-6% -$766 ﹤0.01% 2291
2025
Q1 		$14.1K Buy
689
+42
+6% +$934 ﹤0.01% 2224
2024
Q4 		$16.6K Hold
647
– – ﹤0.01% 2148
2024
Q3 		$10.7K Hold
647
– – ﹤0.01% 2307
2024
Q2 		$12.4K Hold
647
– – ﹤0.01% 2178
2024
Q1 		$15.3K Buy
+647
New +$13.1K ﹤0.01% 2128

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

SignatureFD's NAMS Position: Q1 2026 in Review

SignatureFD sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 647 shares — an estimated $22.7K sold.

SignatureFD first reported a position in NAMS in Q1 2024 and held it in 8 quarters. The position peaked at $22.7K in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • SignatureFD reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
  • SignatureFD sold 647 NewAmsterdam Pharma shares in Q1 2026, an estimated $22.7K.
  • SignatureFD first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 8 quarters.
  • SignatureFD's NewAmsterdam Pharma position peaked at $22.7K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.